Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Eli Lilly raised its 2026 sales forecast to $91-92 billion, driven by strong Zepbound weight-loss drug sales. While smaller competitor Viking Therapeutics shows promise with its VK2735 candidate demonstrating encouraging clinical trial results, Eli Lilly's diversified pipeline and market leadership position it well to withstand competition. Viking offers high upside potential but carries significant clinical and regulatory risks.

11/11/2026, 5:34 PM • The Motley Fool

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

The article compares two pharmaceutical giants for 2027 investment. Johnson & Johnson offers stability with a 6% revenue growth, lower P/E ratio of 42.59, and strong free cash flow of $19.7B, but faces patent expirations and litigation risks. Eli Lilly demonstrates explosive 44.7% revenue growth driven by GLP-1 drugs like Mounjaro and Zepbound, commanding a premium valuation (P/E 47.05), with significant future growth potential but concentrated revenue dependency.

11/11/2026, 3:00 PM • The Motley Fool

GLP-1 RAs & Incretin-based Therapies Competitive Landscape Analysis: Key Developments by 200+ Companies Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive competitive landscape report on GLP-1 receptor agonists and incretin-based therapies, covering 200+ pipeline drugs from 180+ active players. The report highlights approved drugs like MOUNJARO (tirzepatide) and OZEMPIC (semaglutide), with 30+ therapies in late-stage development and 60+ in mid/early stages. Key indications include obesity, type 2 diabetes, and cardiovascular outcomes. Recent developments include positive Phase III results for retatrutide, survodutide, and other dual/triple agonists from major pharmaceutical companies.

11/11/2026, 1:00 PM • GlobeNewswire

My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell

The article discusses a long-term investment strategy for building a 'forever portfolio' with stocks suitable for buy-and-hold investors. It emphasizes the importance of adopting a different mindset when investing for longer time horizons, though the specific stock recommendations are behind a paywall.

11/11/2026, 6:30 AM • The Motley Fool

Type 2 Diabetes Clinical Trial and Competitive Landscape Analysis: 200+ Key Companies Shaping the Future of Type 2 Diabetes Therapeutics Space | DelveInsight

DelveInsight released a comprehensive report on the Type 2 Diabetes competitive landscape, analyzing 200+ pipeline drugs from 170+ active players. The report highlights recent approvals including Eli Lilly's FOUNDAYO (orforglipron) and Novo Nordisk's once-weekly insulin options, alongside promising pipeline therapies targeting various mechanisms of action. Key developments include positive Phase III results for CagriSema, elecoglipron, and other novel GLP-1 receptor agonists, with approximately 60+ drugs in late-stage development.

11/10/2026, 1:00 PM • GlobeNewswire

1 Reliable ETF I'm Buying Forever, Even if the Stock Market Crashes

The author recommends the Vanguard S&P 500 ETF (VOO) as a reliable long-term investment despite current market volatility and crash concerns. VOO offers diversification across 500 large U.S. companies, a low 0.03% expense ratio, and has historically recovered from all 27 bear markets it has experienced, averaging 12.5% annual returns since 2010. The author suggests dollar-cost averaging to mitigate timing risk in uncertain market conditions.

11/10/2026, 12:00 PM • The Motley Fool

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

11/10/2026, 11:00 AM • GlobeNewswire

Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

Eli Lilly has surged over 50% in the past year with 39% revenue growth driven by its GLP-1 drugs Zepbound and Mounjaro, but trades at a steep 45x P/E ratio. Novo Nordisk has lagged with only 6% revenue growth but trades at just 10x earnings and could see significant upside if its higher-dose Wegovy gains traction. The author favors Novo Nordisk as the better value play despite Eli Lilly's superior growth, citing valuation concerns and increased competition ahead.

11/10/2026, 10:44 AM • The Motley Fool

Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?

Gilead Sciences stock has surged 38% year-to-date, hitting all-time highs and outperforming the S&P 500. The pharmaceutical company's growth has improved significantly with strong results across HIV, liver disease, and oncology segments, while Veklury revenue declined post-COVID. Trading at a forward P/E of 17 with a 1.92% dividend yield, analysts suggest the stock remains attractively valued despite its recent gains.

11/10/2026, 5:49 AM • The Motley Fool

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

11/09/2026, 9:45 AM • The Motley Fool

Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.

Eli Lilly's market capitalization has grown to nearly 9 times that of Novo Nordisk, driven by their dominance in the GLP-1 weight loss drug market. Lilly captured 63% U.S. market share by early 2025 compared to Novo's 36%, aided by superior manufacturing infrastructure, greater weight loss efficacy of tirzepatide (20% vs. 14%), and advantages of its oral drug Foundayo. Meanwhile, Novo faced setbacks including mixed data on CagriSema and a failed heart drug trial.

11/09/2026, 6:10 AM • The Motley Fool

Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?

Novo Nordisk's Wegovy GLP-1 weight-loss pill has surpassed 5 million prescriptions and is outperforming the company's injectable version, supporting its strategic shift to a volume-driven business model. However, the company faces headwinds from lower pricing, weak earnings, and intensifying competition from Eli Lilly's rival GLP-1 pill. The stock offers an attractive 4.4% dividend yield and historically cheap valuation, making it appealing for aggressive dividend investors willing to bet on the turnaround, though more conservative investors should wait for clearer progress on profitability.

11/08/2026, 3:15 PM • The Motley Fool

Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?

Novo Nordisk reported strong Q3 2026 results driven by its oral weight-loss pill, which generated $810 million in revenue with over 3 million prescriptions. The company raised its full-year guidance and the stock jumped 6% post-earnings. With upcoming catalysts including international expansion of oral Wegovy, new product launches like CagriSema, and promising pipeline candidates, analysts suggest the company is staging a comeback after a difficult two-year period.

11/07/2026, 6:20 PM • The Motley Fool

Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials

While Eli Lilly dominates the GLP-1 weight-loss drug market and Novo Nordisk struggles to regain ground, Pfizer is positioning itself as a surprise contender. After dropping its original GLP-1 candidate, Pfizer acquired an alternative drug in development and is now running 10 late-stage trials. The company's key differentiator is a monthly injection option, which could offer greater convenience than competitors' weekly or daily dosing. With a high dividend yield of 5.5% and an inflection point potentially closer than Wall Street believes, Pfizer may represent an overlooked opportunity for long-term dividend investors.

11/07/2026, 4:15 PM • The Motley Fool

Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?

Eli Lilly raised its 2026 revenue guidance to $91-92 billion from $85-87 billion, driven by strong GLP-1 drug sales including Mounjaro and Zepbound. Despite a 57% stock run-up and expensive 47x P/E valuation, the author argues the stock remains a buy due to massive untapped market potential for GLP-1 drugs across obesity, cardiovascular disease, addiction treatment, and potentially anti-aging applications.

11/07/2026, 1:30 PM • The Motley Fool